Australasian Gastro-intestinal Trials Group

Neuroendocrine tumors often keep growing despite treatment with somatostatin analogues, drugs that slow tumor growth and reduce hormone production. When that happens, doctors add peptide receptor radionuclide therapy (PRRT), a targeted radiotherapy, but they do not know whether c…

This phase II trial is testing whether adding a targeted radiation dose and the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with advanced esophageal cancer who have trouble swallowing. The study will enroll 54 adults whose cancer has sprea…

This study tests whether using real-time MRI to guide radiation therapy can better control abdominal cancer that has spread to a few spots. Thirty adults with certain cancers (like colorectal or breast) will receive high-dose, precisely targeted radiation. The goal is to improve …

This phase 2 trial is testing whether combining two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—can help keep advanced bile duct cancer from growing after initial chemotherapy. The study will enroll 40 adults with locally advanced or metastatic cholangio…